论文部分内容阅读
目的观察CD3AK细胞体外杀瘤活性及其治疗中晚期原发性肝癌的效果。方法采用抗CD3单克隆抗体（CD3McAb）辅以少量rlL—2和PHA诱导外周血淋巴细胞制备CD3AK细胞。体外实验用MTT法测定其对K562、Hela—3和H7402肿瘤细胞株杀瘤活性，然后应用于临床，将140例中晚期肝癌患者随机分为三组，A组5l例（CD3AK细胞十化疗），B组45例（单纯化疗），C组44例（单用CD3AK细胞治疗）。结果CD3AK细胞体外对K562、Hela－3和H7402细胞株杀瘤率分别为78．54％、34．09％和64．37％，抗肿瘤效应的最佳时期在培养的第7～10天之间；临床治疗部分缓解率（PR）A、B、C组分别为45．1％、17．7％和20．5％，A、B两组比较有显著性差异（P＜0．o1）。结论CD3AK细胞是继LAK细胞后又一为有效的杀瘤细胞，临床应用安全可靠、有效，在中晚期肝癌辅助治疗中有着良好的应用价值，合理结合其它疗法可增强疗效。
Objective To observe the anti-tumor activity of CD3AK cells in vitro and its efficacy in the treatment of advanced primary liver cancer. Methods CD3AK cells were induced by peripheral blood lymphocytes induced by anti-CD3 monoclonal antibody (CD3McAb) supplemented with a small amount of rlL-2 and PHA. In vitro MTT assay was used to determine the tumorigenicity of K562, Hela-3, and H7402 tumor cell lines, and then applied to the clinic. 140 patients with advanced liver cancer were randomly divided into three groups, group A and group 5l (CD3AK cells ten chemotherapy). There were 45 patients in group B (chemotherapy alone) and 44 patients in group C (treated with CD3AK alone). Results The killing rates of CD3AK cells against K562, Hela-3 and H7402 cell lines in vitro were 78.54%, 34.09% and 64.37% respectively. The best time for antitumor effect was in the 7th to 10th days of culture. The clinical remission rate (PR) in group A, B and C was 45.1%, 17.7% and 20.5%, respectively. There was a significant difference between groups A and B (P<0.o1). . Conclusion CD3AK cells are another effective killer tumor cells after LAK cells. The clinical application is safe, reliable and effective. It has a good application value in the adjuvant treatment of advanced hepatocellular carcinoma. Rational combination with other therapies can enhance the efficacy.